论文部分内容阅读
Objective: A pilot study to test the feasibility andefficacy of high dose IFO and standard dose ADR andDTIC with G-CSF support in treatment of advanced softtissue sarc0ma (STS). Methods: 35 patients of no priorchemotherapy with methetatic or locally advancedunresecfable STS were treated by this regimen, including 18rhabdomyosarromas, 7 malignant fibrous histiocytomas, 2neurofibrosarcomas, 2 fibrosarcomas, 2 leiomyosarcomas, 2synoviosarcomas, and 2 malignant hemangiopericytomas.IFO dose was 2 g/m2 on day 1-5 (with mesna uroprotection),ADR 50mg/m2 on day 1 and DTIC 250 mg/m2 on day 1-5.G-CSF (2 μg/d) was administered on day 6 to 15 or untilrecovery of leukocytes account. The cycles were repeatedevery 3 weeks. Result: There were five complete responses(CR including pathologic CR) and eleven partial responsesfor overall 46% objective response rate- Most responseswere observed within two cycles. The median survival was15 months. Following CR, two patients remain disease freeat 45 and 28 months, respectively. 6/120 (5%) cycles werecomplicated by grade IV neutropenia, 46/120 (38%) cycleshad grade III neutropenia. No patients had treatmentrelated deaths. Nonhematologic toxicity consistedpredominantly of anorexia and vomiting. No other severetoxicities were seen, especially no severe cardiotoxicity.Concluson: This regimen is well tolerated and hassubstantial benefits for patients with advanced soft tissuesarcomas.
Objective: A pilot study to test the feasibility and efficiency of high dose IFO and standard dose ADR andDTIC with G-CSF support in treatment of advanced softtissue sarc0ma (STS). Methods: 35 patients of no priorchemotherapy with methetatic or locally advancedunresecfable STS were treated by This regimen, including 18rhabdomyosarromas, 7 malignant fibrous histiocytomas, 2neurofibrosarcomas, 2 fibrosarcomas, 2 leiomyosarcomas, 2synoviosarcomas, and 2 malignant hemangiopericytomas.IFO dose was 2 g/m2 on day 1-5 (with mesna uroprotection), ADR 50mg/m2 on day 1 and DTIC 250 mg/m2 on day 1-5.G-CSF (2 μg/d) was administered on day 6 to 15 or untilrecovery of leukocytes account. The week was repeatedevery 3 weeks. Result: There were five complete responses( CR including pathologic CR) and eleven partial responsesfor overall 46% objective response rate- Most responseswere observed within two cycles. The median survival was15 months. Following CR, two patientsties disease freeat 45 and 28 mo Nths, respectively. 6/120 (5%) cycles werecomplicated by grade IV neutropenia, 46/120 (38%) cycleshad grade III neutropenia. No patients had treatmentrelated deaths. Nonhematologic toxicity consistedpredominantly of anorexia and vomiting. No other severetoxicities were seen, Especially no severe cardiotoxicity.Concluson: This regimen is well tolerated and hassubstantial benefits for patients with advanced soft tissuesarcomas.